1. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014;63:194–200.
4. Park SY, Moon SM, Kim B, et al. Appropriateness of antibiotic prescriptions during hospitalization and ambulatory care: a multicentre prevalence survey in Korea. J Glob Antimicrob Resist 2022;29:253–258.
5. Choi SM, Choo SY. Antimicrobial awareness week. Public Health Wkly Rep 2021;14:3318–3319.
8. Kwon KT. Implementation of antimicrobial stewardship programs. J Korean Med Assoc 2022;65:498–504.
10. Ryu S. The new Korean action plan for containment of antimicrobial resistance. J Glob Antimicrob Resist 2017;8:70–73.
12. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990–1001.
14. Cunha CB. The pharmacoeconomic aspects of antibiotic stewardship programs. Med Clin North Am 2018;102:937–946.
16. Ostrowsky B, Banerjee R, Bonomo RA, et al. Infectious diseases physicians: leading the way in antimicrobial stewardship. Clin Infect Dis 2018;66:995–1003.
19. Hurst AL, Child J, Pearce K, Palmer C, Todd JK, Parker SK. Handshake stewardship: a highly effective rounding-based antimicrobial optimization service. Pediatr Infect Dis J 2016;35:1104–1110.
21. The Communicable and Infectious Diseases Steering Committee Task Group on Antimicrobial Use Stewardship. Antimicrobial Stewardship: Final Reprot to the Public Health Network Council [Internet]. Ottawa (CA): Pan-Canada Public Health Network, c2016 [cited 2022 Dec 12]. Available from:
https://www.phn-rsp.ca/en/docs/antimicrobial-stewardship.pdf
22. Langford BJ, Wu JH, Brown KA, et al. Assessing the impact of antibiotic stewardship program elements on antibiotic use across acute-care hospitals: an observational study. Infect Control Hosp Epidemiol 2018;39:941–946.
23. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
24. Le Coz P, Carlet J, Roblot F, Pulcini C. Human resources needed to perform antimicrobial stewardship teams' activities in French hospitals. Med Mal Infect 2016;46:200–206.
25. Doernberg SB, Abbo LM, Burdette SD, et al. Essential resources and strategies for antibiotic stewardship programs in the acute care setting. Clin Infect Dis 2018;67:1168–1174.
27. Ten Oever J, Harmsen M, Schouten J, et al. Human resources required for antimicrobial stewardship teams: a Dutch consensus report. Clin Microbiol Infect 2018;24:1273–1279.
28. Maeda M, Muraki Y, Kosaka T, et al. Essential human resources for antimicrobial stewardship teams in Japan: estimates from a nationwide survey conducted by the Japanese Society of Chemotherapy. J Infect Chemother 2019;25:653–656.
29. Maeda M, Muraki Y, Kosaka T, et al. The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy. J Infect Chemother 2019;25:83–88.
30. Park SY, Chang HH, Kim B, et al. Human resources required for antimicrobial stewardship activities for hospitalized patients in Korea. Infect Control Hosp Epidemiol 2020;41:1429–1435.
32. Heil EL, Kuti JL, Bearden DT, Gallagher JC. The essential role of pharmacists in antimicrobial stewardship. Infect Control Hosp Epidemiol 2016;37:753–754.
33. Waters CD. Pharmacist-driven antimicrobial stewardship program in an institution without infectious diseases physician support. Am J Health Syst Pharm 2015;72:466–468.
35. Apisarnthanarak A, Lapcharoen P, Vanichkul P, Srisaeng-Ngoen T, Mundy LM. Design and analysis of a pharmacist-enhanced antimicrobial stewardship program in Thailand. Am J Infect Control 2015;43:956–959.
37. Apisarnthanarak A, Kwa AL, Chiu CH, et al. Antimicrobial stewardship for acute-care hospitals: an Asian perspective. Infect Control Hosp Epidemiol 2018;39:1237–1245.
39. Kim HI, Kim SW, Chang HH, Kim HB. A survey of antimicrobial stewardship programs in Korean hospitals. Korean J Med 2014;87:173–181.
43. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988;148:2019–2022.
44. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003;37:180–186.
46. Abbo LM, Cosgrove SE, Pottinger PS, et al. Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis 2013;57:631–638.
47. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109–1115.
48. Hauck LD, Adler LM, Mulla ZD. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol 2004;14:669–675.
51. Patterson PP, Ellingson KD, Backus D, Schmitz E, Matesan M. A syndrome-based approach to antimicrobial stewardship in an Arizona skilled nursing facility-moving the needle through quality improvement. Am J Infect Control 2020;48:1537–1539.
53. Mediwala KN, Kohn JE, Bookstaver PB, et al. Syndrome-specific versus prospective audit and feedback interventions for reducing use of broad-spectrum antimicrobial agents. Am J Infect Control 2019;47:1284–1289.
54. Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther 2020;18:5–15.
55. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529–535.
57. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1435–1486.
59. Williams P, Cotta MO, Roberts JA. Pharmacokinetics/pharmacodynamics of β-lactams and therapeutic drug monitoring: from theory to practical issues in the intensive care unit. Semin Respir Crit Care Med 2019;40:476–487.
60. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588–2598.
61. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669–1674.
62. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012;380:484–490.
65. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032–1039.
66. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. the optimal duration of therapy. Chest 1996;110:965–971.
67. Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012;172:922–928.
70. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003;25:3173–3189.
71. Huang AM, Newton D, Kunapuli A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013;57:1237–1245.
72. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010;51:1074–1080.
75. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics 2003;112:363–367.
76. Srinivas P, Rivard KR, Pallotta AM, et al. Implementation of a stewardship initiative on respiratory viral PCR-based antibiotic deescalation. Pharmacotherapy 2019;39:709–717.
79. Avdic E, Wang R, Li DX, et al. Sustained impact of a rapid microarray-based assay with antimicrobial stewardship interventions on optimizing therapy in patients with gram-positive bacteraemia. J Antimicrob Chemother 2017;72:3191–3198.
80. Coupat C, Pradier C, Degand N, Hofliger P, Pulcini C. Selective reporting of antibiotic susceptibility data improves the appropriateness of intended antibiotic prescriptions in urinary tract infections: a case-vignette randomised study. Eur J Clin Microbiol Infect Dis 2013;32:627–636.
81. Tan TY, McNulty C, Charlett A, Nessa N, Kelly C, Beswick T. Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J Antimicrob Chemother 2003;51:379–384.
82. McNulty CA, Lasseter GM, Charlett A, et al. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother 2011;66:1396–1404.
83. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–474.
87. Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics 2001;108:E75.
88. Patel J, Esterly JS, Scheetz MH, Bolon MK, Postelnick MJ. Effective use of a clinical decision-support system to advance antimicrobial stewardship. Am J Health Syst Pharm 2012;69:1543–1544.
89. Bochicchio GV, Smit PA, Moore R, et al. Pilot study of a web-based antibiotic decision management guide. J Am Coll Surg 2006;202:459–467.
101. Kim B, Kim Y, Hwang H, et al. Trends and correlation between antibiotic usage and resistance pattern among hospitalized patients at university hospitals in Korea, 2004 to 2012: a nationwide multicenter study. Medicine (Baltimore) 2018;97:e13719.
103. Cisneros JM, Neth O, Gil-Navarro MV, et al. Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre. Clin Microbiol Infect 2014;20:82–88.
104. Molina J, Peñalva G, Gil-Navarro MV, et al. Long-term impact of an educational antimicrobial stewardship program on hospital-acquired candidemia and multidrug-resistant bloodstream infections: a quasi-experimental study of interrupted time-series analysis. Clin Infect Dis 2017;65:1992–1999.
106. Owens RC Jr, Shorr AF, Deschambeault AL. Antimicrobial stewardship: shepherding precious resources. Am J Health Syst Pharm 2009;66 Suppl 4:S15–S22.
108. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011;66:2168–2174.
109. Price J, Cheek E, Lippett S, et al. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect 2010;16:1297–1302.
110. Kallen AJ, Thompson A, Ristaino P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009;30:264–272.
111. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987–994.
112. Kim SH, Wi YM. Current strategy and perspective view for preventing Clostridioides difficile infection in acute care facilities. Korean J healthc assoc Infect Control Prev 2021;26:70–82.
118. Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA 2001;285:2871–2879.
122. Korea Disease Control and Prevention Agency. One Health Antimicrobial resistant organism [Internet]. Cheongju (KR): Korea Disease Control and Prevention Agency, c2022 [cited 2022 Dec 12]. Available from:
http://www.kdca.go.kr/nohas/
123. Duke Antimicrobial Stewardship Outbreak Network (DASON). Duke Antimicrobial Stewardship Outreach Network homepage. [Internet]. Durham (NC): DASON, c2016 [cited 2022 Dec 12]. Available from:
https://dason.medicine.duke.edu/
124. Belongia EA, Knobloch MJ, Kieke BA, Davis JP, Janette C, Besser RE. Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis 2005;11:912–920.
125. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24:699–706.
126. Landgren FT, Harvey KJ, Mashford ML, Moulds RF, Guthrie B, Hemming M. Changing antibiotic prescribing by educational marketing. Med J Aust 1988;149:595–599.
128. Weiss K, Blais R, Fortin A, Lantin S, Gaudet M. Impact of a multipronged education strategy on antibiotic prescribing in Quebec, Canada. Clin Infect Dis 2011;53:433–439.
129. Regev-Yochay G, Raz M, Dagan R, et al. Reduction in antibiotic use following a cluster randomized controlled multifaceted intervention: the Israeli judicious antibiotic prescription study. Clin Infect Dis 2011;53:33–41.
130. Garcia Reeves AB, Lewis JW, Trogdon JG, Stearns SC, Weber DJ, Weinberger M. Association between statewide adoption of the CDC's core elements of hospital antimicrobial stewardship programs and rates of methicillin-resistant Staphylococcus aureus bacteremia and Clostridioides difficile infection in the United States. Infect Control Hosp Epidemiol 2020;41:430–437.
131. Yoo M, Madaras-Kelly K, Nevers M, et al. A Veterans' Healthcare Administration (VHA) antibiotic stewardship intervention to improve outpatient antibiotic use for acute respiratory infections: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2022;43:1389–1395.
132. Madaras-Kelly K, Hostler C, Townsend M, et al. Impact of implementation of the core elements of outpatient antibiotic stewardship within veterans health administration emergency departments and primary care clinics on antibiotic prescribing and patient outcomes. Clin Infect Dis 2021;73:e1126–e1134.
133. Kim B, Lee MJ, Moon SM, et al. Current status of antimicrobial stewardship programmes in Korean hospitals: results of a 2018 nationwide survey. J Hosp Infect 2020;104:172–180.